|By PR Newswire||
|February 11, 2014 07:02 AM EST||
WESTBOROUGH, Mass., Feb. 11, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ") Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals Corporation said that, "We are very pleased to achieve this milestone as a Company." He added that, "Listing on NASDAQ will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders. We thank OTC Markets Group for having been a gracious host to RXi for the past 2 years, helping the company move into this new stage of its growth. This accomplishment marks another milestone for RXi as we continue to develop our self-delivering RNAi-based (sd-rxRNA®) technology platform into commercially viable assets."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
SOURCE RXi Pharmaceuticals Corporation
Sep. 29, 2016 06:00 AM EDT Reads: 2,664
Sep. 29, 2016 06:00 AM EDT Reads: 516
Sep. 29, 2016 06:00 AM EDT Reads: 2,749
Sep. 29, 2016 05:45 AM EDT Reads: 1,046
Sep. 29, 2016 05:45 AM EDT Reads: 1,500
Sep. 29, 2016 05:30 AM EDT Reads: 1,144
Sep. 29, 2016 05:30 AM EDT Reads: 2,947
Sep. 29, 2016 05:15 AM EDT Reads: 1,242
Sep. 29, 2016 05:00 AM EDT Reads: 1,635
Sep. 29, 2016 04:45 AM EDT Reads: 1,797
Sep. 29, 2016 04:30 AM EDT Reads: 4,678
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
Sep. 29, 2016 04:00 AM EDT Reads: 1,211
Sep. 29, 2016 04:00 AM EDT Reads: 1,813
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
Sep. 29, 2016 03:45 AM EDT Reads: 4,823
SYS-CON Events announced today that ReadyTalk, a leading provider of online conferencing and webinar services, has been named Vendor Presentation Sponsor at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. ReadyTalk delivers audio and web conferencing services that inspire collaboration and enable the Future of Work for today’s increasingly digital and mobile workforce. By combining intuitive, innovative tec...
Sep. 29, 2016 03:30 AM EDT Reads: 3,033